Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
June 28 2024 - 7:00AM
Verve Therapeutics, a clinical-stage biotechnology company
pioneering a new approach to the care of cardiovascular disease
with single-course gene editing medicines, today announced the
appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board
of directors. Dr. Tatsis currently serves as executive vice
president, chief regulatory and quality officer, of Vertex
Pharmaceuticals. Ms. Morrison currently serves as chief executive
officer and director of Q32 Bio Inc.
“We are thrilled to have Nia and Jodie join Verve’s board of
directors, lending their decades of impressive experience leading
and advising pharmaceutical and biotech companies through critical
stages in drug development, manufacturing, and commercialization,”
said Sekar Kathiresan, M.D., co-founder and chief executive officer
of Verve Therapeutics. “We look forward to their valuable insights
as we focus on pipeline execution with the continued advancement of
the Heart-2 clinical trial of VERVE-102 targeting the PCSK9 gene,
the clinical trial initiation of VERVE-201 targeting the ANGPTL3
gene, and continued progress on our earlier stage LPA program.”
“I deeply admire Verve’s mission to change the trajectory of how
cardiovascular disease is treated around the world. Their goal of
transforming the chronic care model to single-course gene editing
medicines is an important step as we look to improve the lives of
people with heart disease,” said Dr. Tatsis. “I look forward to
working closely with the Verve leadership team and the board as the
company continues to further progress its PCSK9, ANGPTL3, and LPA
programs.”
“The opportunity to address the millions of people around the
world with cardiovascular disease with a one-time treatment
represents a truly important mission. I am excited to partner with
the Verve team as they continue these efforts,” said Ms. Morrison.
“Verve is well-positioned to become a distinguished leader in the
cardiovascular space, supported by its impressive team and
transformative science.”
Nia Tatsis, Ph.D., joined Vertex Pharmaceuticals in 2017 and
serves as the company’s executive vice president, chief regulatory
and quality officer. Prior to joining Vertex, Dr. Tatsis held
positions of increasing responsibility at pharmaceutical companies
including Sanofi, Pfizer, and Wyeth. Most recently, she served as
vice president, head of global regulatory affairs, of the Sanofi
Genzyme Business Unit. Dr. Tatsis currently serves as a member of
the leadership council of the International Institute of New
England. Previously, she served as a staff scientist and research
fellow in immunology and vaccine development at the Wistar
Institute. Dr. Tatsis received her Ph.D. in cell and molecular
biology from the University of Vermont and completed a postdoctoral
research fellowship in immunology at Thomas Jefferson University.
She holds a B.S. in biology from Temple University.
Jodie Morrison, chief executive officer and director of Q32 Bio
Inc., brings two decades of biopharmaceutical leadership experience
across private and public biotechnology and pharmaceutical
companies from start-up to commercial stage. Ms. Morrison was
previously chief executive officer of Cadent Therapeutics until its
sale to Novartis in 2021. Ms. Morrison also served as interim chief
executive officer of Keryx Biopharmaceuticals, Inc. (executed its
merger of equals with Akebia Therapeutics, Inc. in 2018), acting
chief operating officer of Syntimmune, Inc. (acquired by Alexion
Pharmaceuticals, Inc.), and president and chief executive officer
of Tokai Pharmaceuticals, Inc., where she oversaw the company’s
successful initial public offering (IPO) in 2014. Ms. Morrison
currently serves as an advisor to Atlas Venture, where she
previously served as a venture partner, and as a member of the
board at Rectify Pharma and of the board of managers at Life
Science Cares. Ms. Morrison holds a B.A. in neuroscience from Mount
Holyoke College.
About Verve Therapeutics Verve
Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic
medicines company pioneering a new approach to the care of
cardiovascular disease, potentially transforming treatment from
chronic management to single-course gene editing medicines. The
company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 –
target genes that have been extensively validated as targets for
lowering low-density lipoprotein cholesterol (LDL-C), a root cause
of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and
VERVE-102 are designed to permanently turn off
the PCSK9 gene in the liver and are being developed
initially for heterozygous familial hypercholesterolemia (HeFH) and
ultimately to treat patients with established ASCVD who continue to
be impacted by high LDL-C levels. VERVE-201 is designed to
permanently turn off the ANGPTL3 gene in the liver and is
initially being developed for homozygous familial
hypercholesterolemia (HoFH) and for refractory hypercholesterolemia
where patients still have high LDL-C despite treatment with
maximally-tolerated standard of care therapies. For more
information, please visit www.VerveTx.com.
Cautionary Note Regarding Forward Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve substantial risks and
uncertainties, including statements regarding the company’s
research and development plans, and the potential advantages and
therapeutic potential of the company’s programs. All statements,
other than statements of historical facts, contained in this press
release, including statements regarding the company’s strategy,
future operations, future financial position, prospects, plans and
objectives of management, are forward-looking statements. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. These risks and uncertainties
include, but are not limited to, risks associated with the
company’s limited operating history; the company’s ability to
timely submit and receive approvals of regulatory applications for
its product candidates; advance its product candidates in clinical
trials; initiate, enroll and complete its ongoing and future
clinical trials on the timeline expected or at all; correctly
estimate the potential patient population and/or market for the
company’s product candidates; replicate in clinical trials positive
results found in preclinical studies and/or earlier-stage clinical
trials of VERVE-101, VERVE-102, and VERVE-201; advance the
development of its product candidates under the timelines it
anticipates in current and future clinical trials; obtain, maintain
or protect intellectual property rights related to its product
candidates; manage expenses; and raise the substantial additional
capital needed to achieve its business objectives. For a discussion
of other risks and uncertainties, and other important factors, any
of which could cause the company’s actual results to differ from
those contained in the forward-looking statements, see the “Risk
Factors” section, as well as discussions of potential risks,
uncertainties and other important factors, in the company’s most
recent filings with the Securities and Exchange Commission and in
other filings that the company makes with the Securities and
Exchange Commission in the future. In addition, the forward-looking
statements included in this press release represent the company’s
views as of the date hereof and should not be relied upon as
representing the company’s views as of any date subsequent to the
date hereof. The company anticipates that subsequent events and
developments will cause the company’s views to change. However,
while the company may elect to update these forward-looking
statements at some point in the future, the company specifically
disclaims any obligation to do so.
Investor ContactJen RobinsonVerve Therapeutics,
Inc.jrobinson@vervetx.com
Media ContactAshlea
Kosikowski1ABashlea@1abmedia.com
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart
From Oct 2023 to Oct 2024